Past performance is no guarantee of future results. All performance presented prior to the index inception date is back-tested performance. Back-tested performance is not actual performance, but is hypothetical. The inception date of the Syntax US Medical Innovation Index (“the Index”) is October 21, 2022. The back-tested calculations are based on the same methodology that was in effect when the index was officially launched. However, back-tested data may reflect the application of the index methodology with the benefit of hindsight. No theoretical or back-tested approach can account for all market factors and the impact of decisions that might have been made during the actual operation of an index. Actual returns may differ from, and be lower than, back-tested returns, which are not necessarily predictive of future returns. Charts and graphs are provided for illustrative purposes only.
The Syntax US Medical Innovation Index is the property of Syntax LLC, which calculates and maintains the Index. Syntax® is a registered trademark of Syntax LLC and its affiliate Locus LP. FIS™ is a trademark of Locus LP for Locus LP’s “Functional Information System”.
Index performance does not represent actual fund or portfolio performance and such performance does not necessarily reflect the actual investment experience of any investor. An investor cannot invest directly in an index. In addition, the results actual investors might have achieved would have likely differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in a portfolio invested in accordance with an index. None of the Syntax Indices or the benchmark indices portrayed herein charge management fees or incur brokerage expenses, and no such fees or expenses were deducted from the performance shown; provided, however, that the returns of any investment portfolio invested in accordance with such indices would be net of such fees and expenses. Additionally, none of these indices lend securities, and no revenues from securities lending were added to the performance shown. Performance shown is unaudited and subject to revision. This site may include materials and documents containing forward-looking statements which are based on our expectations and projections as of the date made. Past returns are not necessarily predictive of future returns.
Beta is a measure of relative risk, calculated as the covariance of the Index’s returns with those of a benchmark divided by the variance of the benchmark’s returns. Volatility is the annualized standard deviation of index returns. Sharpe ratio is a risk-adjusted measure calculated using standard deviation of returns and excess return to determine reward per unit of risk. A higher Sharpe ratio indicates better risk-adjusted performance. Beta, volatility, and Sharpe ratio are calculated using monthly returns. Weighted-Average Stock Price-to-Earnings Ratio (P/E Ratio) is the harmonic weighted average of the ratio of each stock’s share price to its trailing-12-month earnings per share. Weighted-Average Stock Price-to-Book Value Ratio (P/B Ratio) is the harmonic weighted average of the ratio of each stock’s market price to its book value. Dividend Yield is the arithmetic weighted average of the ratio of each stock’s annual dividend per share to its market price. Price-to-Earnings, Price-to-Book and Dividend Yield are calculated as of 03/31/2024. P/E, P/B, and Dividend Yield are calculated by Syntax via Refinitiv. Top holdings and security classifications used in calculating allocation tables are based on ending weight as of 03/31/2024.
